Navigation Links
Peregrine Pharmaceuticals Reports Positive Top-Line Results in,Bavituximab Combination Therapy Trial in Advanced Cancer Patients

- 50% of All Evaluable Patients Receiving Combination of Bavituximab Plus
Chemotherapy Achieved Objective Tumor Response or Stable Disease -

- 75% of Patients Receiving Combination of Bavituximab Plus Gemcitabine
Achieved Objective Tumor Response or Stable Disease -

- 50% of Patients Receiving Combination of Bavituximab Plus
Carboplatin/Paclitaxel Achieved Objective Tumor Response -

- Trial Results Support Advancing to Exploratory Phase II Efficacy
Studies Currently Planned for Later This Year -

TUSTIN, Calif., May 31, 2007 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today reported positive top-line results of its Phase lb open label trial of bavituximab in combination with chemotherapy. This trial was designed to assess the safety and tolerability of bavituximab in combination with common chemotherapy agents in advanced cancer patients with metastatic disease who had failed prior therapy. Patients in the trial were also assessed for tumor response.

In the trial, the safety profile of bavituximab in combination with chemotherapy appeared similar to that seen in advanced cancer patients undergoing chemotherapy alone. The combination of bavituximab and chemotherapy showed positive signs of clinical activity, achieving objective tumor response or stable disease in 50% of the patients who were evaluable for tumor response. Patients receiving bavituximab in combination with gemcitabine demonstrated an even greater response, with 75% achieving an objective tumor response or stable disease, while 50% of patients receiving bavituximab with carboplatin/paclitaxel demonstrated an objective tumor response. Data from this study are be
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
2. Peregrine Pharmaceuticals Highlights Significant Advances in the Companys Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting
3. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
4. Data Presented at AACR Meeting Show Peregrines Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer
5. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
11. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:1/23/2015)... Fla. , Jan. 23, 2015  HyGreen, Inc., a ... agreement and partnership with RCA Medical, a subsidiary of ... . Each year, hundreds of millions ... care-associated infections as organisms are transmitted from patient to ...
(Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities & ... for shareholders detailing why a "YES" vote to increase the ... As we reflect upon the 2014 fiscal year ...
(Date:1/23/2015)... Gem Pharmaceuticals announced today that the initial soft tissue ... Phase 2 clinical trial.  This open-label study will assess ... (an investigational medication), in approximately 30 adults as first-line ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO GPX-150 is ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
(Date:1/22/2015)... The U.S. Pharmacopeial Convention is pleased to ... Pharmacy Services at North Carolina State’s College of Veterinary ... Beal Award for Distinguished Volunteer Service—the organization’s highest award. ... contributions of volunteer experts to direct its work to ...
(Date:1/22/2015)... The City of West Hollywood hosted a news conference on ... anniversary of the Supreme Court decision Roe v. Wade, which legalized ... the Roe vs. Wade decision and the fight to protect a ... City of West Hollywood Councilmember Abbe Land. “We need to continue ...
(Date:1/22/2015)... 2015 Padre Murphy's and Owner Tom Boyle ... Pro Player Health Alliance (PPHA). The PPHA's passion for ... everyone, including NFL greats, treated for obstructive sleep apnea (OSA) ... supporting the cause in the valley. The most recent plans ...
(Date:1/22/2015)... 23, 2015 Angelweddingdress is a famous wedding ... its customers to follow it on Facebook, Twitter, and Pinterest. ... Day gift. Angelweddingdress draws a lottery every week. , Moreover, ... Feb. 28, 2015. Click Angelweddingdress homepage for more ...
(Date:1/22/2015)... 2015 The federal court overseeing thousands of ... Court, Southern District of West Virginia has upheld a $2 ... first bellwether trial. In an Order dated January 21st, the ... finding that C.R. Bard had not proven a miscarriage of ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4
... ... women and men - have not brought the anticipated decline in deaths from these diseases, ... Science Center at San Antonio in an opinion piece published in the "Journal of the ... (Vocus) ...
... ROSEMONT, Ill., Oct. 20 Prevalence of lactose intolerance may ... in the latest issue of Nutrition Today .(1) ... of three ethnic groups, reveals that the overall prevalence rate ... percent of European Americans, 10.05 percent of Hispanic Americans and ...
... HOPKINTON, Mass., Oct. 20 Caliper Life Sciences, Inc. ... discussing the company,s third quarter 2009 financial results at ... Hrusovsky, President and Chief Executive Officer and Peter McAree, ... discuss operational and financial results and the company,s outlook ...
... of patients in U.S. hospitals fail to get recommended ... -- A recommended treatment for heart failure is underused ... use of aldosterone antagonist therapy in patients with heart ... heart failure guidelines established by the American College ...
... has heart failure or stroke, study finds , TUESDAY, Oct. ... heart failure and stroke -- and probably their close relatives ... fractures, a new study has found. , Genetic factors might ... shared by the vasculature [blood vessels] and bone," said Dr. ...
... ... annual North American East Coast Rhapsody User Group in Boston, at The Liberty Hotel ... vendor partners showcasing how they utilize Rhapsody to connect and exchange data with other ... Boston, ...
Cached Medicine News:Health News:Experts Issue Call to Reconsider Screening for Breast Cancer and Prostate Cancer 2Health News:Experts Issue Call to Reconsider Screening for Breast Cancer and Prostate Cancer 3Health News:Experts Issue Call to Reconsider Screening for Breast Cancer and Prostate Cancer 4Health News:Experts Issue Call to Reconsider Screening for Breast Cancer and Prostate Cancer 5Health News:Experts Issue Call to Reconsider Screening for Breast Cancer and Prostate Cancer 6Health News:Lactose Intolerance Rates May Be Significantly Lower Than Previously Believed 2Health News:Lactose Intolerance Rates May Be Significantly Lower Than Previously Believed 3Health News:Lactose Intolerance Rates May Be Significantly Lower Than Previously Believed 4Health News:Lactose Intolerance Rates May Be Significantly Lower Than Previously Believed 5Health News:Caliper Life Sciences' Third Quarter 2009 Financial Results Conference Call Notice 2Health News:Heart Failure Treatment Underused 2Health News:Genes May Link Hip Fractures and Heart Disease 2Health News:Genes May Link Hip Fractures and Heart Disease 3Health News:Orion Health™ Rhapsody User Group 2009, Boston Starts Today,New Interoperability Expo Helps Ignite Record Attendance 2Health News:Orion Health™ Rhapsody User Group 2009, Boston Starts Today,New Interoperability Expo Helps Ignite Record Attendance 3Health News:Orion Health™ Rhapsody User Group 2009, Boston Starts Today,New Interoperability Expo Helps Ignite Record Attendance 4
... The AMS Ambicor is a uniquely designed ... of cylinders implanted in the corpora cavernosa ... the scrotum. Patients simply squeeze the pump ... deflate the prosthesis. This closed, fluid-filled system ...
... is an advanced three-part inflatable prosthesis consisting of ... placed in the scrotum and a pair of ... simulates the look and performance of a natural ... technology, the AMS 700 Series now features the ...
... part of the Freedom Urinary Collection ... bags, kits, and accessories designed to ... customers. These leg bags are offered ... 100% latex-free soft, textured medical grade ...
... on delicate urethral tissues. The ... coating provide nearly friction-free movement, ... easy to maintain sterility. You ... its own sterile water, avoiding ...
Medicine Products: